The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | DESTINY-Lung01: cohort expansion results
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the cohort expansion results from the Phase Ib DESTINY-Lung01 trial (NCT03505710), presented by Dr Bob Li at ESMO 2021, which looked at trastuzumab deruxtecan for patients with HER2 mutant non-small cell lung cancer (NSCLC). Overall response rate was 55%, median progression-free survival was 8.2 months, and the median overall survival was 17.8 months, with nearly all patients having tumour shrinkage. Prof. Popat highlights how encouraging these trial results are for patients with NSCLC. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
